Copper-62-ATSM: a new hypoxia imaging agent with high membrane permeability and low redox potential.
暂无分享,去创建一个
Y Yonekura | H Ohtani | J Konishi | Y. Yonekura | Y. Fujibayashi | Yoshiharu Yonekura | J. Konishi | A. Yokoyama | H. Ohtani | Y Fujibayashi | A Yokoyama | H Taniuchi | H. Taniuchi | Junji Konishi | Hiroshi Ohtani | Akira Yokoyama
[1] J. D. Chapman,et al. Radioiodinated 1-(2-fluoro-4-iodo-2,4-dideoxy-beta-L-xylopyranosyl)-2-nitroimidazole: a novel probe for the noninvasive assessment of tumor hypoxia. , 1992, Radiation research.
[2] L. Golberg,et al. Non-invasive assessment of human tumour hypoxia with 123I-iodoazomycin arabinoside: preliminary report of a clinical study. , 1992, British Journal of Cancer.
[3] C. Ng,et al. Kinetic analysis of technetium-99m-labeled nitroimidazole (BMS-181321) as a tracer of myocardial hypoxia. , 1995, Circulation.
[4] B Chance,et al. Evaluation of Cardiac Ischemia by NADH Fluorescence Photography , 1977, Annals of surgery.
[5] C. Dence,et al. Myocardial kinetics of fluorine-18 misonidazole: a marker of hypoxic myocardium. , 1989, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.
[6] A. Nunn,et al. TcO(PnA.O-1-(2-nitroimidazole)) [BMS-181321], a new technetium-containing nitroimidazole complex for imaging hypoxia: synthesis, characterization, and xanthine oxidase-catalyzed reduction. , 1994, Journal of medicinal chemistry.
[7] P. Pedersen,et al. Proton ATPase of rat liver mitochondria: a rapid procedure for purification of a stable, reconstitutively active F1 preparation using a modified chloroform method. , 1984, Analytical biochemistry.
[8] Y. Yonekura,et al. Application of the new zinc-62/copper-62 generator: an effective labeling method for 62Cu-PTSM. , 1992, International journal of radiation applications and instrumentation. Part B, Nuclear medicine and biology.
[9] K. Sakai,et al. A device for recording left ventricular contraction and electrocardiogram in nonworking isolated perfused rat heart. , 1978, Japanese journal of pharmacology.
[10] M. Green,et al. Structure-activity relationships for metal-labeled blood flow tracers: comparison of keto aldehyde bis(thiosemicarbazonato)copper(II) derivatives. , 1990, Journal of medicinal chemistry.
[11] A. Nunn,et al. Synthesis, characterization, and in vitro evaluation of nitroimidazole--BATO complexes: new technetium compounds designed for imaging hypoxic tissue. , 1993, Bioconjugate chemistry.
[12] S. Ochoa. [123] Malic dehydrogenase from pig heart: l-Malate + DPN + ⇆ Oxalacetate + DPNH + H+ , 1955 .
[13] F. Ota,et al. Anisotropic inhibition of energy transduction in oxidative phosphorylation in rat liver mitochondria by tetraphenylarsonium. , 1980, The Journal of biological chemistry.
[14] P. Workman,et al. The novel fluorinated 2-nitroimidazole hypoxia probe SR-4554: reductive metabolism and semiquantitative localisation in human ovarian cancer multicellular spheroids as measured by electron energy loss spectroscopic analysis. , 1995, British Journal of Cancer.
[15] C. H. Bayley,et al. THE PREPARATION OF SOME THIOSEMICARBAZONES AND THEIR COPPER COMPLEXES: PART III , 1960 .
[16] M J Welch,et al. Synthesis and biodistribution of 18F-labeled fluoronitroimidazoles: potential in vivo markers of hypoxic tissue. , 1986, International journal of radiation applications and instrumentation. Part A, Applied radiation and isotopes.
[17] R. Pennington. Biochemistry of dystrophic muscle. Mitochondrial succinate-tetrazolium reductase and adenosine triphosphatase. , 1961, The Biochemical journal.
[18] Y. Fujibayashi,et al. Effects of ischemia-reperfusion injury on myocardial single pass extraction and retention of Cu-PTSM in perfused rat hearts: comparison with 201T1 and 14C-iodoantipyrine. , 1994, Nuclear medicine and biology.
[19] J. Brown,et al. Partition coefficient as a guide to the development of radiosensitizers which are less toxic than misonidazole. , 1980, Radiation research.
[20] D. Petering,et al. Structure-function correlations in the reaction of bis(thiosemicarbazonato) copper(II) complexes with Ehrlich ascites tumor cells. , 1978, Cancer research.
[21] John M. Hoffman,et al. Binding of the hypoxia tracer [3H]misonidazole in cerebral ischemia. , 1987, Stroke.
[22] G. Adams,et al. Electron-affinic sensitization. VII. A correlation between structures, one-electron reduction potentials, and efficiencies of nitroimidazoles as hypoxic cell radiosensitizers. , 1976, Radiation research.
[23] J. D. Chapman,et al. Characteristics of the metabolism-induced binding of misonidazole to hypoxic mammalian cells. , 1983, Cancer research.
[24] J. Downey,et al. Xanthine oxidase: a critical mediator of myocardial injury during ischemia and reperfusion? , 1986, Acta physiologica Scandinavica. Supplementum.
[25] H. Strauss,et al. Comparison of technetium-99m-glucarate and thallium-201 for the identification of acute myocardial infarction in rats. , 1992, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.
[26] W. Rumsey,et al. Effect of graded hypoxia on retention of technetium-99m-nitroheterocycle in perfused rat heart. , 1995, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.
[27] Y. Yonekura,et al. Cu-pyruvaldehyde-bis(N4-methylthiosemicarbazone) (Cu-PTSM), a metal complex with selective NADH-dependent reduction by complex I in brain mitochondria: a potential radiopharmaceutical for mitochondria-functional imaging with positron emission tomography (PET). , 1995, Biological & pharmaceutical bulletin.
[28] A. Lott,et al. Copper as a hypoxic cell sensitizer of mammalian cells. , 1978, The British journal of cancer. Supplement.
[29] Y. Yonekura,et al. A new zinc-62/copper-62 generator as a copper-62 source for PET radiopharmaceuticals. , 1989, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.